MSLN and mesothelioma: These data are in line with the results obtained in the cohort of MPM patients included in the randomized trial, where we documented the presence of functional CD8+ and CD4+ T-cell responses against mesothelin and WT-1, both TAA expressed by mesothelioma (74–76), already before treatment in a proportion of MPM patients (Figure 3).